Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06700841 containing 14C microtracer · 1 trial · 1 indication
cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered
cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered
| Arm | Type | Description |
|---|---|---|
| 2-period, fixed sequence | EXPERIMENTAL | fixed sequence with 2 treatment period |
| Name | Type | Description |
|---|---|---|
| Oral PF-06700841 containing 14C microtracer | DRUG | Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period |
| Oral unlabeled PF-06700841 | DRUG | 60 mg unlabeled PF-06700841 oral dose in 2nd period |
| IV 14C-labeled PF-06700841 | DRUG | 30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period |
Exclusion Criteria: * Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection). * Total 14C radioactivity measured in plasma exceeding 11 mBq/mL * History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test * Use of ...
PF-06700841 containing 14C microtracer is an investigational small molecule being studied in healthy male subjects. It is used in a Phase 1 clinical trial to evaluate the absorption, metabolism, and excretion of the drug using a radioactive 14C-labeled microdose. The study is not designed to treat any disease.
PF-06700841 containing 14C microtracer is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE.
PF-06700841 containing 14C microtracer is in Phase 1 clinical development. It is an investigational drug and is not approved by regulatory authorities. The single Phase 1 trial has been completed.
PF-06700841 containing 14C microtracer has one completed clinical trial, registered as NCT03770039. The trial, titled "Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects," enrolled 6 participants in the Netherlands and was not randomized or blinded.
PF-06700841 containing 14C microtracer is a formulation of PF-06700841 that includes a 14C-labeled microdose, used to track the drug's behavior in the body. The trial combines an unlabeled dose with a 14C-labeled microdose to study how the drug is processed.